Literature DB >> 9258342

Endothelial proteoglycans inhibit bFGF binding and mitogenesis.

K E Forsten1, N A Courant, M A Nugent.   

Abstract

Basic fibroblast growth factor (bFGF) is a known mitogen for vascular smooth muscle cells and has been implicated as having a role in a number of proliferative vascular disorders. Binding of bFGF to heparin or heparan sulfate has been demonstrated to both stimulate and inhibit growth factor activity. The activity, towards bFGF, of heparan sulfate proteoglycans present within the vascular system is likely related to the chemical characteristics of the glycosaminoglycan as well as the structure and pericellular location of the intact proteoglycans. We have previously shown that endothelial conditioned medium inhibits both bFGF binding to vascular smooth muscle cells and bFGF stimulated cell proliferation in vitro. In the present study, we have isolated proteoglycans from endothelial cell conditioned medium and demonstrated that they are responsible for the bFGF inhibitory activity. We further separated endothelial secreted proteoglycans into two fractions, PG-A and PG-B. The large sized fraction (PG-A) had greater inhibitory activity than did PG-B for both bFGF binding and bFGF stimulation of vascular smooth muscle cell proliferation. The increased relative activity of PG-A was attributed, in part, to larger heparan sulfate chains which were more potent inhibitors of bFGF binding than the smaller heparan sulfate chains on PG-B. Both proteoglycan fractions contained perlecan-like core proteins; however, PG-A contained an additional core protein (approximately 190 kDa) that was not observed in PG-B. Both proteoglycan fractions bound bFGF directly, and PG-A bound a significantly greater relative amount of bFGF than did PG-B. Thus the ability of endothelial heparan sulfate proteoglycans to bind bFGF and prevent its association with vascular smooth muscle cells appears essential for inhibition of bFGF-induced mitogenesis. The production of potent bFGF inhibitory heparan sulfate proteoglycans by endothelial cells might contribute to the maintenance of vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258342     DOI: 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  17 in total

Review 1.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

2.  A computational approach for deciphering the organization of glycosaminoglycans.

Authors:  Jean L Spencer; Joel A Bernanke; Jo Ann Buczek-Thomas; Matthew A Nugent
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

3.  Basement membrane and stroke.

Authors:  Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-18       Impact factor: 6.200

4.  The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.

Authors:  Megan S Lord; Christine Y Chuang; James Melrose; Michael J Davies; Renato V Iozzo; John M Whitelock
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

Review 5.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

6.  Inhibition of histone acetyltransferase by glycosaminoglycans.

Authors:  Jo Ann Buczek-Thomas; Edward Hsia; Celeste B Rich; Judith A Foster; Matthew A Nugent
Journal:  J Cell Biochem       Date:  2008-09-01       Impact factor: 4.429

7.  Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts.

Authors:  Helen M Nugent; Robert Tjin Tham Sjin; Desmond White; Luther G Milton; Roberto J Manson; Jeffrey H Lawson; Elazer R Edelman
Journal:  J Vasc Surg       Date:  2007-09       Impact factor: 4.268

8.  Endothelial cell capture of heparin-binding growth factors under flow.

Authors:  Bing Zhao; Changjiang Zhang; Kimberly Forsten-Williams; Jun Zhang; Michael Fannon
Journal:  PLoS Comput Biol       Date:  2010-10-28       Impact factor: 4.475

9.  Sucrose octasulfate regulates fibroblast growth factor-2 binding, transport, and activity: potential for regulation of tumor growth.

Authors:  Michael Fannon; Kimberly Forsten-Williams; Matthew A Nugent; Kalvin J Gregory; Chia Lin Chu; Adrienne L Goerges-Wildt; Dipak Panigrahy; Arja Kaipainen; Carmen Barnes; Cathy Lapp; Yuen Shing
Journal:  J Cell Physiol       Date:  2008-05       Impact factor: 6.384

10.  Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2.

Authors:  Masako Tanaka; Maki Yamaguchi; Masayuki Shiota; Yukiko Kawamoto; Katsuyuki Takahashi; Azusa Inagaki; Mayuko Osada-Oka; Akihito Harada; Hideki Wanibuchi; Yasukatsu Izumi; Katsuyuki Miura; Hiroshi Iwao; Yasuyuki Ohkawa
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.